The immunosuppression status inside GBM is demonstrated by upregulation of PD-L1 in almost 50% of primarily diagnosed and 45% of recurrent GBM cases (9), and PD-L1 expression is negatively correlated with prognosis (10, 11). Here, CD274 is linked to glioblastoma.